Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$26.4MCash on Hand
8.6mo Cash Runway
Follow BMEA by emailGet an email when BMEA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BMEA, unsubscribe in one click. Privacy
📣 What BMEA Says Is Next
fourth quarter of 2026 · “Both trials include a 26-week primary endpoint, with topline data anticipated in the fourth quarter of 2026.”
Company press release, May 11, 2026 · SEC filing
first quarter of 2027 · “Cash runway projected into the first quarter of 2027 SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026, and provided a business update.”
Company press release, May 11, 2026 · SEC filing
fourth quarter of 2026 · “First patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on track with topline 26-week data expected in the fourth quarter of 2026”
Company press release, May 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings Reported Q3 2026 net loss of $6.2 million and cash of $26.8 million, with R&D expenses of $8.5 million. Phase II COVALENT-211 enrollment is complete with topline data expected in Q1 2027, and cash runway runs into Q2 2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 14, 2026 ·
Clinical trial Reported Week 4 topline Phase 1 GLP-131 results for oral GLP-1 receptor agonist BMF-650, designed for better tolerability and reduced GI effects. Preclinical monkey data showed up to ~15% body weight reduction after 28 days. Form 8-K · SEC filing · Press release
Sep 22, 2026 ·
Clinical trial Biomea Fusion updated the expected timing for topline results from its ongoing Phase I GLP-131 trial of BMF-650 in obese, otherwise healthy volunteers, now expected in October 2026. Form 8-K · SEC filing
Sep 22, 2026 ·
Financing Biomea Fusion proposes a public offering of shares of common stock and pre-funded warrants, underwritten by Konik Capital Partners, under a $300.0 million shelf registration. Offering amounts and price are left blank in this preliminary filing. The stock closed at $1.71 on September 21, 2026. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Active Trial · Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets Registry primary completion date, not a results date
Jun 2027 · Phase 2 · Recruiting · Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BMEA holds $26.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $9.2M/quarter from operations,
an estimated runway of 8.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 9 months +30
Shelf registration (S-3, Aug 2025) +10
Going-concern doubt in the latest 10-Q +15There is substantial doubt about our ability to continue as a going concern, and we will require substantial additional capital to finance our operations.10-Q, Nov 2026
Share count 72,678,080 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BMEA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMEA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.